Needham analyst Gil Blum has maintained their bullish stance on RCKT stock, giving a Buy rating today.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Gil Blum’s rating is based on several key factors that highlight Rocket Pharmaceuticals’ potential for growth. The company is making progress with its pivotal study on RP-A501 for Danon disease, with dosing still ongoing and an update expected in the first half of 2025. Additionally, Rocket is working towards resolving regulatory issues related to RP-L102 and aims to finalize its BLA submission within the year.
Financially, Rocket Pharmaceuticals is in a strong position, having ended the year with $372 million, which includes recent financing efforts. This financial stability is expected to support operations until the third quarter of 2026. Despite lowering the price target to $42 due to increased dilution and adjusted launch timelines, the overall outlook remains positive, justifying the Buy rating.